Specifically, it enables clinicians to tailor therapeutic approaches, including surgical planning, adjuvant therapy selection, and follow-up monitoring, thereby optimizing clinical outcomes for HCC patients with different TP53 statuses. The gene discussed is TP53; the disease is hepatocellular carcinoma.